GLIPR1

Across TCGA pan-cancer cohorts, GLIPR1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GLIPR1 data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GLIPR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLIPR1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where GLIPR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.303	0.506	.002	53	view →
CCRCC	OS	Tertile	All	0.721	0.991	.003	30	view →
GBM	OS	Tertile	All	0.244	0.520	.013	9	view →
LUAD	DFS	Quartile	All	0.831	0.485	.017	7	view →
LSCC	OS	Median	All	0.747	0.899	.014	6	view →
HNSC	OS	Quartile	All	0.830	0.626	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GLIPR1–PDAC (DFS)

Open the PDAC breakdown →